tbuckley/cabot-search huggingface dataset:
Death certification and epidemiological research. Medical Services Study Group of the Royal College of Physicians of London.
Authors: G Aber, P Adnitt, L Alexander, J Bavley, I Brown, C Carmalt, F Clarke, M Clarke, A Clymo, G Cochrane, R Cockel, A Cole, H Cook, S Cope, J Cunningham, M Cuthill, S Davies, T Davies, J Delaney, A Douglas, C Dukes, N Dyer, K Ellenbogen, C Evans, G Evans-Jones, W Fielding, J Fisher, J Friend, I Gray, F Gunstone, B Hanley, D Hill, G Honey, S Hughes, A Johnston, E Jones, Sherwood Jones, Howei Jones, C Jones, S Kalinowski, A Kendall, M Kubik, F Leyland, P Manfield, J Meecham, B Miles, B Muldoon, G Murray, A Mccandless, J Mcconnell, R Mcconnell, K Mcdowell, G Mcmillan, J Nye, H Parry, A Paton, J Peaston, D Evans, K Prowse, G Richards, D Riddoch, J Ross, R Ross, H Savage, C Schwartz, D Short, B Smith, C Swan, P Thorn, D Thursby-Pelham, D Tibbutt, J Turner, W Van't Hoff, J Walkden, B Walker, F Weinstein, A Wilson, J Wood, J Woodrow, G Youngs, J Zacharias
Journal: BMJ (1978)

The cause of death shown on 191 death certificates was compared with the cause indicated by the hospital case notes, the consultants' opinions, and the necropsy findings. All 191 deaths occurred among medical hospital patients aged under 50. In 39 cases there was a major discrepancy between the two sources over the cause of death and in another 54 ther was a minor but epidemiologically important difference. Death certificates are not primarily intended for epidemiological research, but researchers often rely on them. This and other studies have shown, however, that death certificates are often inaccurate records of the cause of death--even coroner's certificates issued after a coroner's necropsy. The accuracy of death certificates might be improved if coroners consulted clinicians more closely and if senior hospital staff completed hospital death certificates.
The Shibboleths of Tuberculosis.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract LB-092: TKI insensitive role of EGFRconfers TKI resistance via PKCδ
Authors: Pei-chih Lee, Mien-chie Hung
Journal: Cancer Research (2019)

Abstract EGFR TKI-insensitive pathway confers heterogeneous mechanisms of TKI resistance via PKCδ in EGFR-mutant lung cancer. Multiple mechanisms of resistance to EGFR tyrosine kinase inhibitors (TKIs) have been identified in EGFR-mutant non-small cell lung cancer (NSCLC); however, recurrent resistance to EGFR TKIs due to the heterogeneous mechanisms underlying resistance within a single patient remains a major challenge in the clinic. Here, we report a role of EGFR heterodimer-mediated nuclear PKCδ as a common axis across multiple known TKI-resistance mechanisms. Specifically, we demonstrate that TKI-inactivated EGFR dimerizes with other membrane receptors implicated in TKI resistance to promote PKCδ nuclear translocation. Moreover, the level of nuclear PKCδ is upregulated in a significant portion of patients (~41.5%) with TKI-resistant NSCLC and is associated with TKI response in patients. The combined inhibition of PKCδ and EGFR induces marked regression of resistant NSCLC tumors with EGFR mutations. These results provide mechanistic insights into the role of the EGFR-PKCδ axis in TKI-resistance and suggest an EGFR addiction in TKI-resistant EGFR-mutant NSCLC. Citation Format: Pei-chih Lee, Mien-chie Hung. TKI insensitive role of EGFRconfers TKI resistance via PKCδ [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-092.
Dr. Fanous and Colleagues Reply
Authors: AYMAN H. FANOUS , M.D., EDWIN J. van den OORD , Ph.D., BRIEN P. RILEY , Ph.D., STEVEN H. AGGEN , Ph.D., MICHAEL C. NEALE , Ph.D., KENNETH S. KENDLER , M.D., F. ANTHONY O’NEILL , M.D., DERMOT WALSH , M.B., F.R.C.P.I.
Journal: American Journal of Psychiatry (2006)
THE PROPOSED CONSTITUTION FOR STATE SOCIETIES.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bilateral parotid gland enlargement and hyperlipoproteinemia
Authors: H. B. Kaltreider
Journal: JAMA (1969)

Sjögren's syndrome was the initial diagnosis of the physicians who referred five patients with bilateral, noninflammatory parotid gland enlargement. This diagnosis was not confirmed in any case. All five patients had elevated plasma triglyceride concentrations and mild diastolic hypertension. Increased intake of alcoholic beverages, abnormal glucose tolerance, and moderate obesity were frequently present. Massive replacement of the parotid gland tissue by fat was observed in two biopsy specimens. Restriction of calories, alcoholic beverages, and the percent of calories from carbohydrate resulted in regression of parotid gland size in three patients observed for more than three months. A modest short-term reduction in size of the parotid gland occurred in one other patient over a five-week period. Hypertriglyceridemia was also ameliorated by this dietary regimen.
Innocent murmurs
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Allergic Reactions to Drugs and Biological Agents
Authors: John A. Anderson
Journal: JAMA (1992)

AN ADVERSE reaction to a drug or a biological agent is an undesirable and usually unanticipated response independent of the intended therapeutic or diagnostic purpose of the medication.<sup>1</sup>Although the exact frequency of adverse reactions to drugs and biological agents is unknown, each year approximately 1 to 2 million Americans experience a drug reaction, usually a skin eruption.<sup>2</sup>Of all hospitalizations in the United States, 2% to 5% may be due to adverse drug reactions.<sup>3</sup>It has been estimated that as many as 30% of hospitalized patients may experience an adverse drug event. A study based on a computerized surveillance system in a 520-bed tertiary care hospital determined that 2% of the 36000 admissions in 1 year were due to adverse drug reactions.<sup>3</sup>Of these reactions, 0.2% were severe, life-threatening, and allergic-like (anaphylaxis/anaphylactoid) in nature. In 37665 medical inpatients in Boston, Mass, 23% experienced adverse skin
Damaging Dispute
Authors: R. S. Murley
Journal: BMJ (1975)

Bradford Soap Works, located in Chester, England, was in such dire circumstances that disaster was nearly certain. Pat Marso, the corporate renewal professional who masterminded the resuscitation, struggled through the six-month transition period right along with the troubled manufacturer. By installing systems, operational disciplines, and a new corporate strategy, the firm has emerged from certain failure to hard-won status as a leader in its industry. Marso9s firm won the Turnaround Management Association9s International Turnaround of the Year Award for 2001.
Abstract 27: Volume and Density of Calcium in the Ascending Thoracic Aorta, When Present, Predict Incident Coronary Heart Disease Beyond Coronary Artery Calcium: the Multi-Ethnic Study of Atherosclerosis
Authors: Isac C Thomas, Nketi Forbang, Matthew Allison, Erin Michos, Wendy Post, Robyn McClelland, WT Longstreth, Nathan Wong, Matthew Budoff, Michael Criqui
Journal: Circulation (2017)

Introduction: Coronary artery calcium (CAC) volume and density differentially predict coronary heart disease (CHD) beyond traditional CVD risk factors. Whether similar associations exist for ascending thoracic aortic calcium (ATAC) volume and density are unknown. We hypothesized that ATAC volume and density predict CHD independent of the pooled cohort equations (PCE) and CAC. Methods: The Multi-Ethnic Study of Atherosclerosis followed 6,814 participants free of clinical CVD at recruitment. Cardiac CT was performed at baseline. For this analysis, only those with prevalent ATAC were included (necessary for evaluation of density). Cox regression was used to estimate associations of ATAC volume and density with incident CHD (fatal/non-fatal MI and cardiac arrest), with adjustment for the PCE and CAC volume and density. The incremental predictive value of ATAC volume and density was evaluated by area under receiver operating characteristic curves (AUC). Results: Of the total cohort, 233 (3.4%) had prevalent ATAC. In these participants, 29 CHD events occurred over 10.3 years. After simultaneous adjustment for the PCE, ATAC and CAC volumes and densities, ATAC alone was associated with CHD, with one standard deviation (SD) higher natural log ATAC volume associated with a 76% greater risk [HR 1.76 (95% CI 1.07-2.87)], and one SD lower ATAC density associated with a 57% lower risk [0.43 (0.26-0.71)]. The PCE, CAC volume and CAC density were not significantly associated with CHD. A model containing the PCE, CAC volume and density had an AUC of 0.584 (0.467-0.701) for incident CHD prediction. Adding ATAC volume and density to the model improved the AUC to 0.703 (0.588-0.817) (see table). Conclusions: ATAC was uncommon in a cohort free of baseline clinical CVD. However, when ATAC was present, both ATAC volume and density were independently associated with incident CHD. Furthermore, in these participants, the PCE and CAC poorly discriminated incident CHD, and ATAC volume and density substantially improved risk prediction.
GYNECOLOGY FOR THE INSANE.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endocrinology
Authors: Nelson B. Watts
Journal: JAMA (1996)

Several recent studies have given us a better understanding of the management of some common endocrine diseases and documented the efficacy of new therapies for others. For the treatment of osteoporosis, Liberman et al<sup>1</sup>evaluated alendronate sodium, an amino bisphosphonate, in 994 women in a multicenter, placebo-controlled trial. Treatment with 10 mg of alendronate sodium daily for 3 years produced significant increases of bone density at the lumbar spine (about 8%), proximal femur, and total body. The incidence and severity of new vertebral fractures was significantly reduced by alendronate treatment. Safety and tolerance of alendronate were excellent. As with all bisphosphonates, alendronate must be taken on an empty stomach to ensure absorption. It should be used with caution (if at all) in patients with impaired renal function, and should not be used in patients with hypocalcemia. Pak et al<sup>2</sup>evaluated slow-release sodium fluoride in a placebo-controlled trial involving
Toxic Substances from Coal Energy: An Overview
Authors: Carl M. Shy
Journal: Environmental Health Perspectives (1979)

Environmental concerns over increased coal consumption are fully justified by the past history of coal use. Although improved technology has provided some safeguards, increased utilization will require mining practices, emission control technologies, and waste disposal procedures that are not yet fully integrated into the routine use of the coal energy system. The Committee on Health and Evnironmental Effects of Increased Coal Utilization identified six critical environmental issues which are of concern: coal mine worker health and safety, reclamation of arid lands from surface mining, the health effects of coal combustion products, toxic trace elements in coal combustion wastes, acid fallout, and global effects of carbon dioxide in the atmosphere. This presentation addresses the first four of these issues.
Augmentation of skin test reactivity and lymphocyte blastogenesis in patients with AIDS treated with transfer factor
Authors: J. T. Carey
Journal: JAMA (1987)

Nine patients with the acquired immunodeficiency syndrome (AIDS) were administered four doses of pooled transfer factor obtained from the lymphocytes of three healthy controls and three homosexuals with stable lymphadenopathy and serum antibody to the human immunodeficiency virus. Before receiving transfer factor, all patients exhibited anergy to skin test antigens. After four weeks of transfer factor therapy, six of seven patients tested had at least one skin test response. Lymphocyte blastogenic responses to phytohemagglutinin rose from a stimulation index of 6.77 ±1.31 before treatment to 19.77 ±6.24 after four weeks of transfer factor therapy. Smaller but significant increases were also seen in blastogenic responses to antigens. Improvements in immune responses diminished after administration of transfer factor was halted. Thus, administration of transfer factor to patients with AIDS resulted in partial immune reconstitution. Further studies are indicated to examine the clinical efficacy of this immune response modifier in the treatment of AIDS. (<i>JAMA</i>1987;257:651-655)
Free Papers
Authors: T. W. L. Scheeren, J. O. Arndt, I. Sehulze-Neick, J. H. Nürnberg, F. Uhlemann, N. A. Haas, F. Berger, C. Opitz, F. X. Kleber, R. Rossaint, R. Hetzer, P. E. Lange, D. Annane, A. S. Blanc, J. C. Raphael, Ph. Gajdos, M. Maggiorini, S. Brimioulle, P. Lejeune, M. Delcroix, F. Vermeulen, J. Stephanazzi, R. Naeije, S. Petros, H. Schädlich, I. Lehmann, L. Engelmann
Journal: Intensive Care Medicine (1996)
Chemonucleolysis
Authors: P. H. Wright
Journal: JAMA (1990)

<h3>To the Editor.—</h3> The Diagnostic and Therapeutic Technology Assessment (DATTA) article on chemonucleolysis<sup>1</sup>contains significant omissions and inaccuracies. For example, anaphylaxis is an important adverse effect of chemonucleolysis but its incidence is exaggerated. Postmarketing surveillance carried out by the manufacturers between 1982 and 1988 shows an overall incidence of 0.46%, but during 1987 and 1988 it was only 0.18%. A recent panEuropean survey of chemonucleolysis has suggested a similar rate of anaphylaxis at 0.2%.<sup>2</sup>Also, while postmarketing surveillance suggests that anaphylaxis occurs more frequently in females (0.68%) than in males (0.18%), this difference is not as great as that (6- to 10-fold) suggested in the article. It is stated in the DATTA article that the dose of chymopapain to be used is between 1000 and 6000 U, whereas only 2000 to 4000 pKat is recommended for treatment of a single disk. Much space is taken up with summarizing
Cholesterol lowering and the reduction of coronary heart disease risk
Authors: B. M. Rifkind
Journal: JAMA (1986)

Cholesterol is an essential yet potentially dangerous molecule. As recently described by Brown and Goldstein<sup>1</sup>in their Nobel Laureate lecture, the very property of cholesterol that makes it essential in cell membranes, namely, its absolute insolubility in water, also makes it potentially lethal. When it accumulates in the arterial wall it cannot be readily mobilized, and its presence eventually leads to the development of an atherosclerotic plaque and its sequelae. Brown and Goldstein also described the potential for errant cholesterol deposition to be aggravated by its dangerous tendency to exchange passively between blood lipoproteins and cell membranes. To transport cholesterol safely in the blood, its concentration must be kept sufficiently low and its tendency to escape from the bloodstream must be controlled. The serious consequences of high cholesterol concentrations are readily apparent in familial hypercholesterolemia (FHC). Fortunately, its homozygous form is rare: one in 1 million in the population.
Loop Device Reported Equal of Oral Contraceptives
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiac Auscultation Skills of Physicians in Training
Authors: Arthur D. Silk
Journal: JAMA (1997)

<h3>To the Editor.</h3> —Apparently every generation of physicians rediscovers its own ineptitude. Drs Mangione and Nieman<sup>1</sup>are apparently disturbed that both internal medicine and family practice trainees were so strikingly wrong at identifying 12 important and commonly encountered cardiac events. Rarely has the cliche "So what else is new?" been so apt. Thirty-five years ago, one of my duties as chief medical resident in a prestigious New York City teaching hospital was to arrange teaching rounds for practicing physicians who served on our voluntary teaching faculty. Almost none of the physicians who were responsible for teaching students and residents could regularly recognize the murmur of mitral regurgitation. Austin Flint and Graham Steell murmurs were loftily discussed but never identified. I was secretly amused at how often atrial fibrillation at a rate of 80 beats per minute was identified either as regular sinus rhythm or at best as premature beats. Medical educators are